Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A11 | Q9UPY5 | 15/20 | 1.00 |
| ▸ | VDAC2 | P45880 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erastin SCHEMBL31385520 | 1.00 | SLC7A11 (1.00) | SLC7A11VDAC2HIF1ALMNAMAPK1 | |
| Erastin SCHEMBL22213543 | 1.00 | SLC7A11 (1.00) | SLC7A11VDAC2HIF1ALMNAMAPK1 | |
| Erastin SCHEMBL29370998 | 1.00 | SLC7A11 (1.00) | SLC7A11VDAC2HIF1ALMNAMAPK1 | |
| SCHEMBL13633718 | 0.94 | SLC7A11 (0.89) | SLC7A11VDAC2HIF1ALMNA | |
| SCHEMBL1593568 | 0.94 | SLC7A11 (0.88) | SLC7A11VDAC2HIF1ALMNAMAPK1 | |
| SCHEMBL25793246 | 0.93 | SLC7A11 (0.87) | SLC7A11VDAC2HIF1ALMNA | |
| SCHEMBL5440840 | 0.92 | SLC7A11 (0.85) | SLC7A11VDAC2HIF1ALMNA | |
| SCHEMBL14222558 | 0.92 | SLC7A11 (0.85) | SLC7A11VDAC2HIF1ALMNA | |
| SCHEMBL4519119 | 0.92 | SLC7A11 (0.85) | SLC7A11VDAC2HIF1ALMNAMAPK1 | |
| SCHEMBL4463410 | 0.91 | SLC7A11 (0.84) | SLC7A11VDAC2HIF1ALMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | KOJIN THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250108036-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | LIFECEUTIX CO., LTD. (KR) | 2025-04-03 | — | — | US | disclosed |
| CN-119548483-A | Application of aloe-emodin in preparing medicine for treating cisplatin-induced acute kidney injury | 延安大学 | 2025-03-04 | — | — | CN | disclosed |
| CN-118987230-A | Application of I-type collagen/Slc 7a11 regulation shaft in vascular remodeling | 蔡菁菁 | 2024-11-22 | — | — | CN | disclosed |
| EP-4431102-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | Lifeceutix Co., Ltd. (KR) | 2024-09-18 | — | — | EP | disclosed |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | WAVEBREAK INC (US) | 2024-06-27 | — | — | US | disclosed |
| CN-117695393-A | Application of GPX4 inhibitor in preparation of medicament for treating scleroderma skin fibrosis | 复旦大学附属华山医院 | 2024-03-15 | — | — | CN | disclosed |
| CN-117582418-A | Co-delivery system of chemical drug and nucleic acid drug, and preparation method and application thereof | 天津医科大学 | 2024-02-23 | — | — | CN | disclosed |
| US-20230226185-A1 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | Kojin Therapeutics, Inc. | 2023-07-20 | — | — | US | disclosed |
| WO-2009108384-A2 | COMPOUNDS AND COMPOSITIONS THAT CAUSE NON-APOPTOTIC CELL DEATH AND USES THEREOF | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2009-09-03 | — | — | WO | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | PROLEXYS PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| US-20080299076-A1 | Compunds and compositions that cause non-apoptotic cell death and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-12-04 | — | — | US | disclosed |
| US-20080220454-A1 | Identification of genotype- selective anti-tumor agents | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-09-11 | — | — | US | disclosed |
| US-7358262-B2 | Identification of genotype-selective anti-tumor agents | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-04-15 | — | — | US | disclosed |
| US-7358262-B2 | Identification of genotype-selective anti-tumor agents | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2008-04-15 | — | — | US | disclosed |
| WO-2008013840-A2 | ERASTIN ANALOGS AND USES THEREOF | TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-01-31 | — | — | WO | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
| US-20070161644-A1 | Erastin analogs and uses thereof | STOCKWELL BRENT R | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080299076-A1 | Compunds and compositions that cause non-apoptotic cell death and uses thereof | BAD, CASP3, BAX | SLC7A11 2266/4885VDAC2 801/4885HIF1A 910/4885 |
| US-20070161644-A1 | Erastin analogs and uses thereof | ERAP2, ERAP1, ERAL1 | SLC7A11 1250/4885VDAC2 3980/4885HIF1A 928/4885 |
| US-20230226185-A1 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | AIFM2, GPX4, SLC40A1 | SLC7A11 44/4885VDAC2 2370/4885HIF1A 168/4885 |
| US-20260034094-A1 | COMPOSITIONS AND METHODS FOR INDUCING FERROPTOSIS | AIFM2, GPX4, HMOX1 | SLC7A11 30/4885VDAC2 610/4885HIF1A 326/4885 |
| US-20240207270-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING LIPID METABOLISM | CPT2, PC, SREBF2 | SLC7A11 906/4885VDAC2 553/4885HIF1A 726/4885 |
| US-20250108036-A1 | COMPOSITIONS FOR REMOVING SENESCENT CELLS AND USES THEREOF | GLA, LIMS1, TP53 | SLC7A11 4786/4885VDAC2 517/4885HIF1A 1737/4885 |
| US-20090214465-A1 | Quinoxaline Derivatives as Antitumor Agents | VDAC3, VDAC2, VDAC1 | SLC7A11 565/4885VDAC2 2/4885HIF1A 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.